FindMyKOL

Thomas Pressly, MD

Basic profile

Shriners Hospitals for Children - Shreveport

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionShreveport, LA · South CentralSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publication2010Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Thomas Pressly is a Rheumatology/Immunology physician affiliated with Shriners Hospitals for Children - Shreveport. OpenAlex indexes 23 publications with 648 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
23publications

Publications indexed by OpenAlex. Counts exclude supporting files.

648citations

Citations across these publications.

13h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
19companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AbbVie
    Program year20256 paymentsResearch
    $11,677
  • Amgen Inc.
    Program year202515 payments
    $373
  • ABBVIE INC.
    Program year202516 payments
    $310
All 57 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    27.7%
    Gabapentinoids10.7%
    Gabapentin82%Pregabalin18%
    Part D≥99 patients
    Nonsteroidal Anti-inflammatory Drug5.4%
    Meloxicam100%
    Part D≥64 patients

    + 7 more classes in this area

  • Cancer & immunology

    20.4%
    Folate Analog Metabolic Inhibitor12.4%
    Methotrexate98%Methotrexate Sodium3%
    Part D≥122 patients
    TNF inhibitor2.9%
    Enbrel43%Humira(Cf) Pen31%Humira(Cf)16%Humira9%
    Part D<11 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    20%
    Corticosteroid18.3%
    Prednisone100%
    Part D≥144 patients
    Proton pump inhibitor0.7%
    Omeprazole100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”